Cargando…

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

The risk of death due to heart disease and stroke is up to four times higher in individuals with diabetes compared to individuals without diabetes. Most guidelines that address treatment of dyslipidemia in patients with diabetes consider diabetes a cardiovascular disease (CVD) “risk equivalent” and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinberg, Helmut, Anderson, Matt S, Musliner, Thomas, Hanson, Mary E, Engel, Samuel S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3673969/ https://www.ncbi.nlm.nih.gov/pubmed/23761972 http://dx.doi.org/10.2147/VHRM.S44330

Ejemplares similares

Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy
por: Tarantino, Nicola, et al.
Publicado: (2017)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI
por: Patel, Chinmay, et al.
Publicado: (2019)

Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
por: Vattimo, Antonio Carlos Amedeo, et al.
Publicado: (2020)

Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin
por: Robinson, Jennifer G
Publicado: (2009)

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
por: Górniak, Agata, et al.
Publicado: (2022)

Fixed drug eruption to sitagliptin
por: Gupta, Mrinal, et al.
Publicado: (2015)

Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Hayes, Jennifer, et al.
Publicado: (2016)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Fediuk, Daryl J., et al.
Publicado: (2019)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Stability-indicating RP-HPLC Method for the Simultaneous Determination of Sitagliptin and Simvastatin in Tablets
por: Ramalingam, P., et al.
Publicado: (2014)

Effect of single oral dose of proanthocyanidin on postprandial hyperglycemia in healthy rats: A comparative study with sitagliptin
por: Sulaiman, Amal Ajaweed
Publicado: (2014)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia – a review of its characteristics
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrome With Diabetes
por: Watanabe, Kaneyuki, et al.
Publicado: (2013)

Screening of Fenofibrate-Simvastatin Solid Dispersions in the Development of Fixed-Dose Formulations for the Treatment of Lipid Disorders
por: Górniak, Agata, et al.
Publicado: (2023)

The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population
por: Bhattacharjee, Rana, et al.
Publicado: (2023)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

The Effectiveness of Various Salacca Vinegars as Therapeutic Agent for Management of Hyperglycemia and Dyslipidemia on Diabetic Rats
por: Zubaidah, Elok, et al.
Publicado: (2017)

Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
por: Rotella, Carlo M, et al.
Publicado: (2010)

New combination treatments in the management of diabetes: focus on sitagliptin – metformin
por: Green, Jennifer, et al.
Publicado: (2008)

The Prevalence of Dyslipidemia and Hyperglycemia among Stroke Patients: Preliminary Findings
por: Ali, Iyad, et al.
Publicado: (2019)

Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia
por: Ngo, Minh Dao, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis
por: Meguro, Shu, et al.
Publicado: (2014)

Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC–ESI–MS/MS
por: Ramesh, B., et al.
Publicado: (2015)

Therapeutic Target Achievement in Type 2 Diabetic Patients after Hyperglycemia, Hypertension, Dyslipidemia Management
por: Kang, Ah Young, et al.
Publicado: (2011)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
por: Cho, Yong Kyun
Publicado: (2018)

Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats
por: Ozaki, Kiyokazu, et al.
Publicado: (2018)

Protection by simvastatin on hyperglycemia-induced endothelial dysfunction through inhibiting NLRP3 inflammasomes
por: Lv, Zhen-Huan, et al.
Publicado: (2017)

P02.01. A dietary approach for treating dyslipidemia and hyperglycemia
por: Feuerstein, J, et al.
Publicado: (2012)

Lotus leaf alleviates hyperglycemia and dyslipidemia in animal model of diabetes mellitus
por: Kim, Ah-Rong, et al.
Publicado: (2013)

Nigerian Honey Ameliorates Hyperglycemia and Dyslipidemia in Alloxan-Induced Diabetic Rats
por: Erejuwa, Omotayo O., et al.
Publicado: (2016)

Mapping and Congenic Dissection of Genetic Loci Contributing to Hyperglycemia and Dyslipidemia in Mice
por: Shi, Weibin, et al.
Publicado: (2016)

HM-Chromanone Ameliorates Hyperglycemia and Dyslipidemia in Type 2 Diabetic Mice
por: Park, Jae Eun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5f26r4f29bde08rjk0qsn1e0o